Potential side effects include anaphylaxis and infusion-related reactions such as rash and diarrhea. Gilead's shares rose 1.3% to $62.30, while Merck was up nearly 2% at $76.08. Sotrovimab is a monoclonal antibody specifically directed against the spike protein of SARS-CoV-2 that is designed to block the virus attachment and entry into human cells. The therapy, sotrovimab, is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to the virus. Reporting By Mrinalika Roy in Bengaluru; Editing by Shounak DasguptaOur Standards: The Thomson Reuters Trust Principles.
Potential side effects include anaphylaxis and neural reactions.
( z0 include :ARG1 ( z1 and :op ( z2 anaphylaxis ) :op ( z3 react :ARG2 ( z4 nerve ) ) ) :ARG1-of ( z5 possible ) :ARG2 ( z6 thing :ARG0-of ( z7 effect ) :mod ( z8 side ) ) )
(z0 / include-01
    :ARG1 (z1 / and
              :op1 (z2 / anaphylaxis)
              :op2 (z3 / react-01
                       :ARG2 (z4 / nerve)))
    :ARG1-of (z5 / possible-01)
    :ARG2 (z6 / thing
              :ARG0-of (z7 / effect-03)
              :mod (z8 / side)))
Potential side effects include anaphylaxis and neural reactions .
z6 :mod z8
z6 :ARG0-of z7
z0 :ARG2 z6
z0 :ARG1-of z5
z1 :op1 z2
z0 :ARG1 z1
z3 :ARG2 z4
z1 :op2 z3